Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Myeloma Crowd Radio

Myeloma Crowd Radio

×  

Follow This Show

Stay in the know about new episodes and updates.
Myeloma Crowd Radio brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.

On-Demand Episodes

Now that daratumumab is being used in the clinic, myeloma specialists have more experience with its use. Learn why a new test is in the works to prevent patients from being taken off the drug when they are actually responding and which... more

For over sixty years Dr. Robert Kyle, MD of the Mayo Clinic led the way in myeloma research and was the pioneer that defined and determined early precursor conditions MGUS and smoldering myeloma in the late 1970s and... more

One year ago, we began raising funds for the Myeloma Crowd Research Iniatiive. With the help of an expert Scientific Advisory Board and a knowledgeable Patient Advisory Board, we selected two projects to fund: 1) a CAR T Cell research... more

Stem cell transplants will continue to be a staple of multiple myeloma therapy because they are highly effective. But can we add something before or after transplant to make them even more powerful? With new maintenance therapies... more

Nanotecnology is the study of very small things - won to the atom and molecule level. Researchers at Washingon University have been given a prestigious grant by the NIH to study nanotechnology in cancer and more specifcially, in... more

You may have heard about checkpoint inhibitors - drugs that help take the breaks off the immune system to fight multiple myeloma. Learn more about how this new class of drugs is being used with all types of myeloma treatment and when they... more

The Institute for Clinical and Economic Review's (ICER) Midwest Comparative Effective Public Advisory Council (CEPAC) will hold is inaugural meeting on May 26, 2016 in St. Louis ?to discuss the comparative clinical effectiveness... more

While immunotherapy approaches expand, proteasome inhibitors remain a staple therapy of multiple myeloma. Learn why they work, how they differ, how the new oral version (Ninlaro) is bringing greater convenience to the clinic, why they... more

Myeloma stem cells are believed to cause the growth of multiple myeloma. Many myeloma treatments kill the myeloma plasma cells, but according to William Matsui, MD of the Johns Hopkins Kimmel Cancer Center, these treatments may... more

Melanie House, DPT, NCS of the University of Iowa recently presented at Pat's Myeloma Survival School on physical issues that myeloma patients face before, during and after their treatment. As part of the Muscles for Myeloma series, she... more
Show Extras

Comments

 comments